Mylan Launches Generic Version of Mesnex Injection

Mylan

today announced that its Mylan Institutional business has launched Mesna Injection, 100 mg/mL, packaged in 1,000 mg/10mL multiple-dose vials. This product, which has faced recent shortages in the U.S., is the generic version of Baxter Healthcare Corporation's Mesnex Injection® and is indicated as a prophylactic agent in reducing the incidence of ifosfamide-indused hemorrhagic cystitis.